Key result
MRNA-1273 vaccination and prior SARS-CoV-2 exposure induced higher neutralization capacity and antibody levels; a second dose did not increase levels in pre-exposed individuals.
Why the study?
It was unclear whether a second mRNA vaccine dose is needed to maximize effectiveness in individuals previously exposed to SARS-CoV-2 and what other factors affect responsiveness.
Does COVID-19 mRNA vaccination induce different antibody responses based on prior SARS-CoV-2 exposure, vaccine brand, and patient characteristics in healthcare workers?
Cohort (n=578)
Does COVID-19 mRNA vaccination induce different antibody responses based on prior SARS-CoV-2 exposure, vaccine brand, and patient characteristics in healthcare workers?
A single dose of mRNA vaccine may be sufficient for primary vaccination in previously SARS-CoV-2 exposed healthy individuals, though responses vary by vaccine brand, comorbidities, and smoking status.
Answers are grounded in this paper and cite their sources.
May support single-dose strategies in previously exposed adults; leaves open optimal dosing and variant durability questions.
BACKGROUND: Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize effectiveness in those previously exposed to SARS-CoV-2 and what other factors affect responsiveness. METHODS: We measured IgA, IgG and IgM levels against SARS-CoV-2 spike (S) and nucleocapsid (N) antigens from the wild-type and S from the Alpha, Beta and Gamma variants of concern, after BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccination in a cohort of health care workers (N=578). Neutralizing capacity and antibody avidity were evaluated. Data were analyzed in relation to COVID-19 history, comorbidities, vaccine doses, brand and adverse events. FINDINGS: Vaccination induced robust IgA and IgG levels against all S antigens. Neutralization capacity and S IgA and IgG levels were higher in mRNA-1273 vaccinees, previously SARS-CoV-2 exposed, particularly if symptomatic, and in those experiencing systemic adverse effects (p<0·05). A second dose in pre-exposed did not increase antibody levels. Smoking and comorbidities were associated with 43% (95% CI, 19-59) and 45% (95% CI, 63-18) lower neutralization, respectively, and 35% (95% CI, 3-57%) and 55% (95% CI, 33-70%) lower antibody levels, respectively. Among fully vaccinated, 6·3% breakthroughs were detected up to 189 days post-vaccination. Among pre-exposed non-vaccinated, 90% were IgG seropositive more than 300 days post-infection. INTERPRETATION: Our data support administering a single-dose in pre-exposed healthy individuals as primary vaccination. However, heterogeneity of responses suggests that personalized recommendations may be necessary depending on COVID-19 history and life-style. Higher mRNA-1273 immunogenicity would be beneficial for those expected to respond worse to vaccination and in face of variants that escape immunity such as Omicron. Persistence of antibody levels in pre-exposed unvaccinated indicates maintenance of immunity up to one year. FUNDING: This work was supported by Institut de Salut Global de Barcelona (ISGlobal) internal funds, in-kind contributions from Hospital Clínic de Barcelona, the Fundació Privada Daniel Bravo Andreu, and European Institute of Innovation and Technology (EIT) Health (grant number 20877), supported by the European Institute of Innovation and Technology, a body of the European Union receiving support from the H2020 Research and Innovation Programme. We acknowledge support from the Spanish Ministry of Science and Innovation and State Research Agency through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. L. I. work was supported by PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation. Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400008C). The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in COVID-19 (n=578). COVID-19 mRNA vaccination and prior SARS-CoV-2 exposure vs. Naive individuals and BNT162b2 vaccination was evaluated on IgA, IgG and IgM levels and neutralizing capacity against SARS-CoV-2 antigens (p=<0.05). MRNA-1273 vaccination and prior SARS-CoV-2 exposure induced higher neutralization capacity and antibody levels; a second dose did not increase levels in pre-exposed individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: